Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11735352 | 0.99 | ALDH1A1 (0.72) | KMT2AMEN1ALDH1A1TSHRKDM4E | |
| SCHEMBL8747121 | 0.97 | KMT2A (0.71) | KMT2AMEN1ALDH1A1TSHRKDM4E | |
| SCHEMBL7838949 | 0.95 | KMT2A (0.74) | KMT2AMEN1ALDH1A1TSHRKDM4E | |
| SCHEMBL7279469 | 0.89 | ALDH1A1 (0.71) | KMT2AMEN1ALDH1A1TSHRKDM4E | |
| SCHEMBL7279475 | 0.89 | ALDH1A1 (0.71) | KMT2AMEN1ALDH1A1TSHRKDM4E | |
| SCHEMBL7417537 | 0.87 | KMT2A (0.59) | KMT2AMEN1ALDH1A1TSHRKDM4E | |
| SCHEMBL8928239 | 0.87 | KMT2A (0.65) | KMT2AMEN1ALDH1A1TSHRKDM4E | |
| SCHEMBL3351763 | 0.86 | KMT2A (0.60) | KMT2AMEN1ALDH1A1TSHRKDM4E | |
| SCHEMBL8549452 | 0.84 | KMT2A (0.61) | KMT2AMEN1ALDH1A1TSHRKDM4E | |
| SCHEMBL21540592 | 0.83 | KDM4E (0.76) | KMT2AMEN1ALDH1A1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872236-B2 | Pharmacological agents for treating ocular diseases | CALASIA PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872236-B2 | Pharmacological agents for treating ocular diseases | CALASIA PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| CN-112601513-B | Medicine for treating eye diseases | 普莱克斯医药公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20210154213-A1 | PHARMACOLOGICAL AGENTS FOR TREATING OCULAR DISEASES | CALASIA PHARMACEUTICALS INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210154213-A1 | PHARMACOLOGICAL AGENTS FOR TREATING OCULAR DISEASES | CALASIA PHARMACEUTICALS INC (US) | 2021-05-27 | — | — | US | disclosed |
| CN-112601513-A | Medicine for treating eye diseases | 普莱克斯医药公司 | 2021-04-02 | — | — | CN | disclosed |
| EP-0792883-B1 | Novel derivates of boronic acid, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2000-12-20 | — | — | EP | disclosed |
| EP-0792883-A1 | Novel derivates of boronic acid, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1997-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154213-A1 | PHARMACOLOGICAL AGENTS FOR TREATING OCULAR DISEASES | CRYAA, CRYAB, TTR | KMT2A 4785/4885MEN1 3695/4885ALDH1A1 1822/4885 |
| US-11872236-B2 | Pharmacological agents for treating ocular diseases | CRYAA, CRYAB, TTR | KMT2A 4785/4885MEN1 3695/4885ALDH1A1 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.